News & Updates

Volatility spiked in the broader indexes after the Federal Reserve indicated that it could keep interest rates higher for longer. The Vanguard U.S. Minimum Volatility ETF (NYSEMKT: VFMV) has a mere 0.13% expense ratio, or $1.30 for every $1,000 invested. The Vanguard U.S. Minimum Volatility ETF targets super-safe companies, many of which pay dividends.

Company Seeks To Reorganize Its Finances While Continuing to Operate Its BusinessBETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- iLearningEngines, Inc. (NASDAQ: AILE) (“iLearningEngines,” “ILE” or the “Company”), a leader in AI-powered learning and work automation, today announced that on December 20, 2024 the Company voluntarily initiated Chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware (the “Court”). The Company will seek Court approval to continue ope

Our time-tested methodologies helped investors navigate the market well last week. Here are some of our key performance data from the past three months.

Revenue Decline and Political Debate Surround Acquisition Proposal

NEW YORK (AP) — Anavex Life Sciences Corp. AVXL) on Monday reported a loss of $11.6 million in its fiscal fourth quarter. On a per-share basis, the New York-based company said it had a loss of 14 cents.

Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), can't seem to get enough of Occidental Petroleum (NYSE: OXY). The conglomerate recently purchased another 8.9 million shares of the oil company for $405 million. Buffett's company now owns over 264 million shares worth almost $12.5 billion, totaling more than 28% of Occidental's outstanding shares.

What were the news stories that grabbed your attention in the last 12 months?

Honda and Nissan have opened talks to merge as the two Japanese carmakers confront a “crisis” caused by the shift to electric vehicles (EVs).

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today reported financial results for its fourth

Fort Lauderdale, FL, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm” or the “Company”) (NASDAQ: RIME) – an AI technology and consumer electronics holding company, announced it will pause new capital raising activities for the next six months. In light of the Company's current cash position, combined with a comprehensive assessment of the current market environment and our business operations, our management team has decided to suspend seeking out any new financing plans